Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NASH Drug Cost Concerns On Level With HCV Treatments For Payers

This article was originally published in The Pink Sheet Daily

Executive Summary

OptumRx, Harvard Pilgrim watching closely as Intercept’s Ocaliva nears market entry with claim for primary biliary cholangitis; use restrictions against off-label use in NASH are likely.

You may also be interested in...



Finance Watch: Investors Go Nuts For NASH As Madrigal Raises $300m, Galmed Skyrockets

Public Company Edition: Madrigal and Galmed shares more than doubled after reporting what were viewed as positive results in mid-stage NASH studies, with Madrigal going on to raise $300m on the back of the data. Not all is well for publicly traded firms, however, as Advaxis and Flex Pharma reveal layoffs.

Fatty Liver Diseases: A Public Health Concern, But Market Opportunity

A new epidemiological analysis suggests the increasing number of patients from across the globe with some form of non-alcoholic fatty liver disease promises an effective therapy would be a welcome addition to the armamentarium of liver disease specialists.

Ocaliva In NASH Manageable With Indication-Based Pricing, ICER Roundtable Suggests

Indication-specific pricing could address 'tension' between initial pricing of Ocaliva for orphan condition and later use in large patient population, according to expert roundtable convened by Institute for Clinical and Economic Review.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079332

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel